Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mari Gasparyan"'
Publikováno v:
J Biol Chem
Triple-negative breast cancer (TNBC) is an aggressive cancer subtype for which effective therapies are unavailable. TNBC has a high frequency of tumor protein p53 (Tp53/p53)- and phosphatase and tensin homolog (PTEN) deficiencies, and combined p53- a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97cf8ea09760938e30a43a144145e25
https://doi.org/10.1074/jbc.ra119.010710
https://doi.org/10.1074/jbc.ra119.010710
Autor:
Yuan Zhang, Duxin Sun, Lichao Sun, Joseph Burnett, Feng Zhang, Zhihua Yang, Yuliang Ran, Hebao Yuan, Mari Gasparyan
Publikováno v:
International Journal of Medical Sciences. 16:68-74
Background: MEOX1 is a homeobox transcriptional factor, and plays essential roles in regulating somite development. Our previous study indicated that MEOX1 is a critical molecular target in mesenchymal-like cancer cells in PTEN-deficient Trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b478adee4fa2ac0cef489d474eeed6a8
https://doi.org/10.7150/ijms.27595
https://doi.org/10.7150/ijms.27595
Autor:
Max S. Wicha, Joseph Burnett, Jamie N. Connarn, Hui Jiang, Ila Myers, Lichao Sun, Fangying Xu, Hasan Korkaya, Yajing Liu, Mari Gasparyan, Ning Zhang, Huining He, Duxin Sun, Chang-Ching Lin
Publikováno v:
Oncotarget
// Lichao Sun 1, 2, * , Joseph Burnett 1, * , Mari Gasparyan 1 , Fangying Xu 1 , Hui Jiang 3 , Chang-Ching Lin 1 , Ila Myers 1 , Hasan Korkaya 4 , Yajing Liu 5 , Jamie Connarn 1 , Huining He 6 , Ning Zhang 6 , Max S. Wicha 5 , Duxin Sun 1 1 Departmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e67b8534a0d650554fff3c533ae2c7cd
http://europepmc.org/articles/PMC5239484
http://europepmc.org/articles/PMC5239484
Autor:
Nicholas O. Stevers, Ramdane Harouaka, Chang-Ching Lin, Hui Jiang, Mari Gasparyan, Miao-Chia Lo, Max S. Wicha, Samantha L. Tinsley, Duxin Sun, Rebecca Moody
Publikováno v:
Cancer Letters. 480:51
Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505ab11ecb646fe5019cb9fa2d98bd2d
https://doi.org/10.1016/j.canlet.2020.01.013
https://doi.org/10.1016/j.canlet.2020.01.013
Autor:
Ramdane Harouaka, Rebecca Moody, Nicholas O. Stevers, Miao-Chia Lo, Hui Jiang, Samantha L. Tinsley, Duxin Sun, Chang-Ching Lin, Max S. Wicha, Mari Gasparyan
Publikováno v:
Cancer letters. 438
Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af1f16c9212332fa05b260a63c81b92
https://pubmed.ncbi.nlm.nih.gov/32229161
https://pubmed.ncbi.nlm.nih.gov/32229161
Autor:
Duxin Sun, Rebecca Moody, Samantha L. Tinsley, Max S. Wicha, Chang-Ching Lin, Miao Chia Lo, Mari Gasparyan, Nicholas O. Stevers
Publikováno v:
Cancer Research. 78:2004-2004
Cancer stem cells (CSCs) are a small population of cancer cells that are capable of self-renewal and tumor initiation. As a result, targeting CSCs is a potential therapeutic strategy for preventing cancer relapse and metastasis. Mixed lineage kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09357f93a8b2373e1506b0be92b5bade
https://doi.org/10.1158/1538-7445.am2018-2004
https://doi.org/10.1158/1538-7445.am2018-2004
Publikováno v:
Cancer Research. 76:2509-2509
Many mechanisms have been attributed to de novo and acquired trastuzumab drug resistance in patients with HER2-enriched breast cancer; common mediated resistance is inactivation of the tumor suppressor gene PTEN seen in approximately 40% of patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::086f9c0016d451c117c443dc9e17f5da
https://doi.org/10.1158/1538-7445.am2016-2509
https://doi.org/10.1158/1538-7445.am2016-2509
Autor:
Mari Gasparyan, Duxin Sun, Hui Jiang, Lichao Sun, Yajing Liu, Jamie N. Connarn, Joseph Burnett, Max S. Wicha, Hasan Korkaya
Publikováno v:
Cancer Research. 74:218-218
Introduction: Previous studies showed that 60-80% of Her2+ breast cancers develop Trastuzumab-resistance after one year treatment and more than 50% of Her2+ Trastuzumab-resistant breast cancers have PTEN deletion and increased populations of cancer s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b00bf5245308757932a2dbe61d52ab4
https://doi.org/10.1158/1538-7445.am2014-218
https://doi.org/10.1158/1538-7445.am2014-218